RxDoctor Payments Data

Marc Pritzker, MD

Cardiovascular Disease · Minneapolis, MNNPI 1285673525

Payments from drug & device makers

$92,654in general payments, 2019–2025

Across 84 payments — averaging $1103.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$89K
  • Bayer$3K
  • Abbott$448
  • Endotronix, Inc.$173
  • Picard Medical Inc.$166
  • Abiomed$62

What the payments were for

  • Consulting fees$3,6104%
  • Speaking & faculty fees$78,50085%
  • Travel & lodging$8,3569%
  • Food & beverage$2,1882%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Actelion Pharmaceuticals US, Inc.76$89,204
Bayer1$2,600
Abbott4$448
Endotronix, Inc.1$173
Picard Medical Inc.1$166
Abiomed1$62

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$92,654 in reported general payments places this provider in the 80th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota

Medicare billing

Part B allowed, 2024
$56,318
Medicare patients
220
Services billed
695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan465$5,804,222
UptraviSelexipag144$3,416,908
Tyvaso DpiTreprostinil122$2,898,008
AdempasRiociguat105$1,417,810
WinrevairSotatercept-Csrk47$790,644
LetairisAmbrisentan14$201,703
Tadalafil188$181,396
Ambrisentan38$130,741
Orenitram ErTreprostinil Diolamine12$124,222
EliquisApixaban68$85,023
Bosentan54$76,313
JardianceEmpagliflozin47$61,941
EntrestoSacubitril/Valsartan46$56,351
AdcircaTadalafil12$50,962
Sildenafil Citrate154$39,945

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Bosentan$89,204$9,297,443663 claims
BayerAdempas$2,600$1,417,810105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 451 cardiovascular disease providers in Minnesota.

Other cardiovascular disease in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →